From the publishers of JADPRO

DLBCL Resource Center

Advertisement
FROM THE EDITOR

Welcome to the JADPRO Diffuse Large B-Cell Lymphoma Resource Center! We've curated the most important information, education, and cutting-edge research on this disease state and created our own original resources to empower your practice. We're excited to provide this new offering, and we hope you and your colleagues find it valuable in helping your patients navigate DLBCL diagnosis, treatment, and survivorship. Take a look around, and send us your feedback at editor@advancedpractitioner.com

Lindsey Lyle, MS, PA-C

Ashley Ames, MSN, RN, FNP-BC, OCN
Oncology Nurse Practitioner
Memorial Sloan Kettering Cancer Center

News & Literature Highlights

2021 American Society of Hematology Annual Meeting (Abstract)

The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma

2021 American Society of Hematology Annual Meeting (Abstract)

Planned interim analysis of a phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3)

2021 American Society of Hematology Annual Meeting (Abstract)

Real-world efficacy and safety outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

2021 American Society of Hematology Annual Meeting (Abstract)

Tafasitamab plus lenalidomide versus Pola-BR, R2, and CAR T: Comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed/refractory diffuse large B-cell lymphoma

Oncology and Therapy

Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with Car T-cell therapy: A qualitative study

Cancers

Immunotherapy for diffuse large B-cell lymphoma: Current landscape and future directions

Targeted Oncology

R-Mini-CHOP plus ibrutinib demonstrates promising PFS in newly diagnosed DLBCL

CancerNetwork

Naratuximab emtansine/rituximab yields promising responses in DLBCL

Cancer Cell

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

Clinical Lymphoma, Myeloma & Leukemia

Health-related quality of life, symptoms, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma

Advertisement
Advertisement